国产重组人白介素-11衍生物治疗化疗后血小板减少的临床观察  

Clinical observation on China manufactured recombinant human interleukin-- 11

作　　者：牛伶[1] 焦卫云[1] 孙峰[1] 刘媛媛[1] 李坦[1] 葛磊[1] 李娟[1] 

机构地区：[1]合肥市第一人民医院,安徽合肥230000

出　　处：《药物与人》2014年第10期1-1,共1页Medicine & People

摘　　要：目的：观察国产？重组人白介素-11（rhlL-11）衍生物治疗恶性肿瘤化疗后血小板减少的临床疗效度不良反应。方法：恶性肿瘤化疗结束后出现血小板〈50X109／L的患者30例，其中20例入选治疗组，应用rhIL--11衍生物治疗，每日皮下注射1．5mg；10例入选对照组，不给予rhIL-11衍生物治疗。结果：治疗组血小板恢复至≥（80—100）X109／L的平均时间为5．65土2．37d，明显低于对照组8．90±3．72d（p〈0．05）。治疗蛆中不良反应为：头晕、头痛、肌肉关节疼痛。结论：rhIL-11衍生物治疗恶性肿瘤化疗所致的血小板下降疗效确切，不良反应可耐受。Objective To investigate and evaluate the clinical therapeutic effect and adverse events of China manufactured recombinant human interleukin 11（rhIL--11） de- rivative in the treatment of thromboeytopenia induced by Chemotherapy. Methods 20 tumor patients with chemotherapy--induced thrombocytopenia were included in treatment group. When the platelet count〈50 x 109, patients in the treatment group were given suheutaneous injection of rhlL-- 112 derivative （1.5mg once daily）. While another 10 cases with chemotherapy--induced thrombocytopenia in the control group were not administrated with rhIL--11. Results The mean time of platelet recovery in the treatment group was 5.65土2.37 days, significantly shorter than that 8.90土3.72 days in the control group （p〈0.05）. In the treatment group, the major adverse events were dizziness, head- ache, muscle and joint pain. Conclusion rhIL--11 derivative could be used for the treatment of thrombocytopenia induced by chemotherapy. Adverse reactions can be tolerated.

关 键 词：白介景-11衍生物 血小板减少 恶性肿瘤 化疗 

分 类 号：R730[医药卫生—肿瘤]